Search Result

Isoforms Recommended:	TBK1

Results for "

TBK-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (3) Autophagy (5) Biochemical Assay Reagents (1) Caspase (2) CCR (1) CDK (1) Cyclic GMP-AMP Synthase (1) DNA Stain (1) ERK (1) HSV (1) IFNAR (3) IKK (28) Interleukin Related (4) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (1) Molecular Glues (1) NF-κB (5) p38 MAPK (1) Parasite (1) PARP (1) PDK-1 (1) PI3K (1) PIKfyve (1) PROTACs (3) Reference Standards (2) Small Interfering RNA (siRNA) (3) Sodium Channel (1) STING (18) Target Protein Ligand-Linker Conjugates (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) ULK (3) Wnt (1)
By Research Areas:	Cancer (26) Infection (6) Inflammation/Immunology (21) Metabolic Disease (2) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) CpG ODNs (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Natural
Products

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-152237

TBK1-IN-1	IKK	Cancer
TBK1-IN-1 is a potent and selective TANK binding kinase 1 (TBK1) inhibitor with an IC₅₀ value of 22.4 nM. TBK1-IN-1 inhibits TBK1 downstream target genes cxcl10 and ifnβ expression. TBK1-IN-1 has anticancer activity ^[1].

HY-12453

TBK1/IKKε-IN-2 2 Publications Verification	IKK	Inflammation/Immunology
TBK1/IKKε-IN-2 is a dual *TBK1* and IKKε inhibitor.

HY-176334

TBK1 ligand 2	Ligands for Target Protein for PROTAC IKK	Cancer
TBK1 ligand 2 (Compound 1b) is a *TBK1* inhibitor. TBK1 ligand 2 can be used for synthesis of PROTAC TBK1 degrader-2 (HY-112557) ^[1].

HY-176255

TBK1 degrader-4	Molecular Glues Interleukin Related CCR	Inflammation/Immunology
TBK1 degrader-4 (Compound 30) is a molecular glue degrader targeting *TBK1. TBK1* degrader-4 effectively inhibits cyst growth, alleviates inflammation, and reduces the levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1 degrader-4 is promising for research of autosomal dominant polycystic kidney disease (ADPKD) ^[1].

HY-RS14257

TBK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TBK1 Human Pre-designed siRNA Set A contains three designed siRNAs for TBK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBK1 Human Pre-designed siRNA Set A TBK1 Human Pre-designed siRNA Set A

HY-RS14259

Tbk1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tbk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tbk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tbk1 Rat Pre-designed siRNA Set A Tbk1 Rat Pre-designed siRNA Set A

HY-RS14258

Tbk1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tbk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tbk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tbk1 Mouse Pre-designed siRNA Set A Tbk1 Mouse Pre-designed siRNA Set A

HY-176335

TBK1 ligand 2-C-O-C4-O-C3-O-C-amide	Target Protein Ligand-Linker Conjugates IKK	Cancer
TBK1 ligand 2-C-O-C4-O-C3-O-C-amide is a conjugate of *TBK1* ligand and linker, which can be used in the synthesis of PROTAC TBK1 degrader-2 (HY-112557) ^[1].

HY-173462

TBK1-IN-2	IKK	Cancer
TBK1-IN-2 (Compound A1) is a potent *TBK1* inhibitor (IC₅₀: 775 pM). TBK1-IN-2 binds to TBK1 through stable hydrogen bonds and π-π stacking, inhibiting IRF3 phosphorylation. TBK1-IN-2 synergizes with TNF/IFNγ to enhance immune-mediated tumor cell death. TBK1-IN-2 can be used in cancer immunotherapy research ^[1].

HY-138931

TBK1/IKKε-IN-6	IKK	Cancer
TBK1/IKKε-IN-6 (example 110) is a *TBK1* and IKKε inhibitor, with IC₅₀ values of <100 nM for both TBK1 and IKKε ^[1].

HY-128679

TBK1/IKKε-IN-5	IKK	Cancer
TBK1/IKKε-IN-5 (compound 1) is an orally active *TBK1* and IKKε dual inhibitor, with IC₅₀ values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to *PD-1* and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity ^[1].

HY-124652

TBK1/IKKε-IN-4	IKK	Cancer
TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective *TBK1* and IKKε inhibitor with IC₅₀ values of 13 nM and 59 nM, respectively. TBK1/IKKε-IN-4 shows 100- to 1000-fold less activity against other protein kinases including PDK1, PI3K family members and mTOR ^[1].

HY-U00457

TBK1/IKKε-IN-1	IKK	Cancer
TBK1/IKKε-IN-1 is a dual *TBK1* and IKKε inhibitor extracted from patent US20160376283 A1, Compound 274 in Example 60, has IC₅₀s of <100 nM.

HY-112557

*PROTAC TBK1* degrader-2**	PROTACs IKK	Cancer
PROTAC TBK1 degrader-2 is a Ligands for Target Protein for PROTAC. PROTAC TBK1 degrader-2 is a potent degrader based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) (DC₅₀=15 nM; K_d=4.6 nM) with a maximum efficiency of 96%. PROTAC TBK1 degrader-2 also targets to IkB kinase IKKε (IC₅₀=8.7 nM), with low selectivity over *TBK1* (IC₅₀=1.3 nM) ^[1].

HY-148206

DMX-129	IKK	Cancer
DMX-129 is an ΙΚΚε and *TBK-1* inhibitor with IC₅₀ values of <30 nM for both TBK1 and IKKε ^[1].

HY-13018

MRT67307 20+ Cited Publications	IKK ULK Autophagy	Inflammation/Immunology Cancer
MRT67307 is a dual inhibitor of the IKKε and *TBK-1* with IC₅₀s of 160 and 19 nM, respectively ^[1]. MRT67307 also inhibits *ULK1* and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells .

HY-13018B

MRT67307 dihydrochloride	IKK ULK Autophagy	Inflammation/Immunology Cancer
MRT67307 dihydrochloride is a dual inhibitor of the IKKε and *TBK-1* with IC₅₀s of 160 and 19 nM, respectively ^[1]. MRT67307 dihydrochloride also inhibits *ULK1* and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 dihydrochloride also blocks autophagy in cells .

HY-13018A

MRT67307 hydrochloride	IKK ULK Autophagy	Inflammation/Immunology Cancer
MRT67307 hydrochloride is a dual inhibitor of the IKKε and *TBK-1* with IC₅₀s of 160 and 19 nM, respectively ^[1]. MRT67307 hydrochloride also inhibits *ULK1* and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 hydrochloride also blocks autophagy in cells .

HY-111941

GSK8612 20+ Cited Publications	IKK	Neurological Disease Inflammation/Immunology Cancer
GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC₅₀ of 6.8 for recombinant TBK1 ^[1].

HY-B0713

Amlexanox 15+ Cited Publications AA673; Amoxanox; CHX3673	IKK	Metabolic Disease
Amlexanox (AA673; Amoxanox; CHX3673) is a specific inhibitor of IKKε and *TBK1, and inhibits the IKKε and TBK1* activity determined by MBP phosphorylation with an IC₅₀ of approximately 1-2 μM.

HY-133117

BAY-985 2 Publications Verification	IKK	Cancer
BAY-985, a chemical probe, is a highly potent, orally active and selective ATP-competitive dual inhibitor of *TBK1* and IKKε with IC₅₀s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively. Antitumor efficacy ^[1].

HY-B0713R

Amlexanox (Standard) AA673 (Standard); Amoxanox (Standard); CHX3673 (Standard)	Reference Standards IKK	Metabolic Disease
Amlexanox (Standard) is the analytical standard of Amlexanox. This product is intended for research and analytical applications. Amlexanox (AA673; Amoxanox; CHX3673) is a specific inhibitor of IKKε and *TBK1, and inhibits the IKKε and TBK1* activity determined by MBP phosphorylation with an IC₅₀ of approximately 1-2 μM.

HY-172620

LIB3S0280	IKK Akt Apoptosis PI3K NF-κB CDK Caspase PARP	Cancer
LIB3S0280 is a potent *TBK1* inhibitor with an IC₅₀ value of 493.9 nM. LIB3S0280 exhibits better anticancer effects in pancreatic cancer cell lines with high TBK1 expression. LIB3S0280 inhibits TBK1 downstream signaling pathways, including PI3K/AKT and NF-κB. LIB3S0280 induces G2/M arrest, apoptosis and cellular senescence. LIB3S0280 can be used for pancreatic ductal adenocarcinoma (PDAC) research ^[1].

HY-110341

MRT 68601 hydrochloride	IKK	Cancer
MRT 68601 hydrochloride is a *TBK1* inhibitor with an IC₅₀ value of 6 nM. MRT 68601 hydrochloride inhibits autophagosome formation in lung cancer cells ^[1] .

HY-133117A

(Rac)-BAY-985	IKK	Cancer
(Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective *TBK1* inhibitor with an IC₅₀ of 1.5 nM. Antitumor efficacy ^[1].

HY-14682

GSK319347A 1 Publications Verification	IKK	Inflammation/Immunology
GSK319347A is a dual inhibitor of *TBK1* and IKKε with IC₅₀s of 93 nM and 469 nM, respectively. GSK319347A also inhibits IKK2 with an IC₅₀ of 790 nM.

HY-N2616

Vomicine 1 Publications Verification	STING	Inflammation/Immunology
Vomicine modulates *cGAS-STING-TBK1* signaling pathway, and exhibits anti-inflammatory activity. Vomicine is an alkaloid that can be isolated from Strychnos nux-vomica seeds ^[1] .

HY-156449

STING-IN-7	STING IKK	Inflammation/Immunology
STING-IN-7 is a potent STING inhibitor with an IC₅₀ of 11.5 nM. STING-IN-7 can inhibit the phosphorylation of STING, IRF3, and *TBK1*. STING-IN-7 can be used in the research of autoimmune and inflammatory diseases ^[1].

HY-112693

H-151 Maximum Cited Publications 100 Publications Verification	STING	Inflammation/Immunology
H-151 is a potent, selective and covalent antagonist of STING that has noteworthy inhibitory activity both in cells and in vivo. H-151 reduces TBK1 phosphorylation and suppresses STING palmitoylation. H-151 can be used for the research of autoinflammatory disease ^[1].

HY-N2616R

Vomicine (Standard)	Reference Standards STING	Inflammation/Immunology
Vomicine (Standard) is the analytical standard of Vomicine. This product is intended for research and analytical applications. Vomicine modulates *cGAS-STING-TBK1* signaling pathway, and exhibits anti-inflammatory activity. Vomicine is an alkaloid that can be isolated from Strychnos nux-vomica seeds ^[1] .

HY-160225

ISD sodium 3 Publications Verification	STING	Inflammation/Immunology
ISD (interferon stimulatory DNA) sodium is a non-CpG oligomer from the Listeria monocytogenes genome. When transfected into cells, ISD sodium strongly enhances the expression of IFN-β. This ISD-induced response is mediated by the STING-TBK1-IRF3 signaling axis ^[1].

HY-116282B

Dextran sulfate sodium salt (MW 16000-24000) 2 Publications Verification DSS (MW 16000-24000); DXS (MW 16000-24000)	Biochemical Assay Reagents STING	Others
Dextran sulfate sodium salt (DSS) (MW 16000-24000) is a polymer of dehydrated glucose with a molecular weight of approximately 16000-24000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 16000-24000) induces STING polymerization and *TBK1* activation ^[1].

HY-160477

DC-SX029	PIKfyve NF-κB IKK	Inflammation/Immunology
DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated K_D constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research ^[1] .

HY-13735H

Quinacrine acetate Acriquine acetate	Parasite Sodium Channel DNA Stain Apoptosis	Cancer
Quinacrine (Acriquine) acetate is a small molecule modulator of the cGAS-STING-TBK1 signaling pathway, possessing immune stimulatory activity. Quinacrine acetate has been explored for its potential therapeutic applications in enhancing anti-tumor immunity. Quinacrine acetate can improve the effectiveness of cancer immunotherapies by addressing the poor immunogenicity of various tumors. Quinacrine acetate also presents a promising strategy for overcoming the limitations associated with immune checkpoint inhibitors in cancer treatment.

HY-118326

MRT 68601	Autophagy	Cancer
MRT 68601 is a potent TBK1 inhibitor with the activity of inhibiting autophagosome formation in lung cancer cells. MRT 68601 may have potential effects against targets associated with host-dependent factors identified in SARS-CoV-2 infection. The drug targets involved in MRT 68601 are related to existing FDA-approved drugs and compounds in clinical trials, which can provide support for the development of broad-spectrum antiviral therapies ^[1].

HY-10514

BX795 30+ Cited Publications	PDK-1 IKK Autophagy	Cancer
BX795 is a potent and selective inhibitor of *PDK1, with an IC₅₀* of 6 nM. BX795 is also a potent and relatively specific inhibitor of *TBK1* and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy ^[1] .

HY-178047

UM-242	STING IFNAR Interleukin Related	Neurological Disease Inflammation/Immunology
UM-242 is a STING inhibitor, with an EC₅₀ of 1.70 μM in THP1-Dual cells expressing wild-type STING. UM-242 blocks STING oligomerization and inhibits diABZI-induced phosphorylation of *TBK1* and IRF3, thereby suppressing the transcription of IFNβ and IL6 and reducing IFNβ secretion. UM-242 can be used for the study of STING-dependent inflammatory and neurological diseases ^[1].

HY-178049

UM-259	STING IFNAR Interleukin Related	Neurological Disease Inflammation/Immunology
UM-259 is a STING inhibitor, with an EC₅₀ of 1.50 μM in THP1-Dual cells expressing wild-type STING. UM-259 blocks STING oligomerization and inhibits diABZI-induced phosphorylation of *TBK1* and IRF3, thereby suppressing the transcription of IFNβ and IL6 and reducing IFNβ secretion. UM-259 can be used for the study of STING-dependent inflammatory and neurological diseases ^[1].

HY-152961

STING agonist-28	STING	Infection
STING agonist-28 (CF510) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-152957

STING agonist-24	STING	Infection
STING agonist-24 (CF504) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-152959

STING agonist-26	STING	Infection Cancer
STING agonist-26 (CF508) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-152956

STING agonist-23	STING	Infection Cancer
STING agonist-23 (CF502) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-152958

STING agonist-25	STING	Infection
STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-160222

HSV-60mer sodium	HSV STING	Infection Inflammation/Immunology
HSV-60mer sodium is a 60 bp double-stranded oligonucleotide containing viral DNA motifs that derive from the herpes simplex virus 1 (HSV-1) genome ^[1]. Transfected HSV-60 has been shown to potently induce IFN-β in a Toll-like receptor (TLR)-, DNA-dependent activator of IRFs (DAI)-, and RNA polymerase III (Pol III)-independent, but STING-, TBK1- and IFN regulatory factor 3 (IRF3)-dependent manner.

HY-175714

STING agonist-46	STING	Inflammation/Immunology Cancer
STING agonist-46 is an orally active STING agonist. STING agonist-46 activates the STING signaling pathway, promoting phosphorylation of *TBK1* and IRF3, and secretion of IFN-β and IP-10. STING agonist-46 directly binds to STING and increases its thermal stability. STING agonist-46 demonstrates potent anti-tumor efficacy in B16F10, CT26, and 4T1 mouse models. STING agonist-46 can be used for cancer immunotherapy studies ^[1].

HY-176192

SMU-14a	Toll-like Receptor (TLR) TNF Receptor NF-κB p38 MAPK ERK IKK	Inflammation/Immunology
SMU-14a is a TLR3 inhibitor (IC₅₀: 0.18 µM). SMU-14a inhibits IL-6 secretion in mouse peritoneal macrophages and downregulates TNF-α in human peripheral blood monocytes. SMU-14a exerts anti-inflammatory effects by reducing the phosphorylation of p65, ERK, and TBK1 through NF-κB, MAPK, and IRF3 signaling pathways, and decreasing serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. SMU-14a can be used in the study of acute hepatitis ^[1].

HY-173414

PROTAC STING degrader-3	PROTACs STING NF-κB	Inflammation/Immunology
PROTAC STING degrader-3 (Compound ST9) is a STING PROTAC degrader (DC₅₀: 0.62 μM). PROTAC STING degrader-3 induces STING degradation via the ubiquitin-proteasome pathway. PROTAC STING degrader-3 exerts anti-inflammatory effects by inhibiting STING/TBK1/NF-κB signaling. PROTAC STING degrader-3 has renal protective effects and can be used in the study of acute kidney injury (AKI) (Pink: STING ligand (HY-47709); Blue: E3 ligase CRBN ligand (HY-41547); Black: linker) ^[1].

HY-123929

PAWI-2	MDM-2/p53 Wnt IKK Apoptosis Caspase	Cancer
PAWI-2 is a p53-Activator and Wnt Inhibitor. PAWI-2 inhibits β3-KRAS signaling independent of KRAS. PAWI-2 selectively inhibits phosphorylation of TBK1. PAWI-2 activates apoptosis (activation of caspase-3/7), and induces PARP cleavage. PAWI-2 promotes optineurin translocation into the nucleus and causes G2/M arrest. PAWI-2 reverses cancer stemness and overcomes drug resistance in an integrin β3 KRAS-dependent human pancreatic cancer stem cells (hPCSCs). PAWI-2 inhibits growth of tumors from hPCSCs in orthopic xenograft mice model ^[1] .

HY-177338

STING agonist-45	STING Cyclic GMP-AMP Synthase IFNAR TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
STING agonist-45 is a selective STING agonist (EC₅₀ = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 ⁺ T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases ^[1] .

HY-176180

PROTAC STING degrader-4	PROTACs STING NF-κB IKK	Inflammation/Immunology
PROTAC STING degrader-4 is a nitro-free covalent STING PROTAC degrader with a DC₅₀ of 3.23 μM. PROTAC STING degrader-4 effectively inhibits STING as well as its downstream signaling, such as p-TBK1 and p-NF-κB (p-P65), and immune-inflammatory cytokines. PROTAC STING degrader-4 mitigates kidney and blood inflammation in Cisplatin (HY-17394)-induced acute kidney injury (AKI) mice model ^[1]. Pink: STING ligand (HY-176183); Blue: CRBN ligase ligand (HY-103596); Black: linker (HY-176182); CRBN ligase ligand + linker: HY-176181

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80519

	TBK1 Antibody (YA662)	WB	Human, Mouse, Rat
	TBK1 Antibody (YA662) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TBK1.

HY-P80910

	TBK1 Antibody (YA040) TBK1; NAK; Serine/threonine-protein kinase TBK1; NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1	WB	Human, Mouse, Rat, Hamster
	TBK1 Antibody (YA040) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1.

HY-P86381

	TBK1 Antibody (YA6073) TBK1; NAK; Serine/threonine-protein kinase TBK1; NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	TBK1 Antibody (YA6073) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1.

HY-P86674

	TBK1 Antibody (YA6366) EC 2.7.11.1; FLJ11330; NAK; NF kappa B activating kinase; NF kB activating kinase; NF-kappa-B-activating kinase; Serine/threonine protein kinase TBK 1; Serine/threonine protein kinase TBK1; Serine/threonine-protein kinase TBK1; T2K; TANK binding kinase 1; TANK-binding kinase 1; TBK 1; TBK1_HUMAN.	WB, IHC-P, IHC-F, IF-Tissue	Human, Rat, Mouse
	TBK1 Antibody (YA6366) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification